Identifying Common Genetic Risk Factors of Diabetic Neuropathies

Type 2 diabetes mellitus (T2DM) is a global public health problem of epidemic proportions, with 60–70% of affected individuals suffering from associated neurovascular complications that act on multiple organ systems. The most common and clinically significant neuropathies of T2DM include uremic neuropathy, peripheral neuropathy, and cardiac autonomic neuropathy. These conditions seriously impact an individual’s quality of life and significantly increase the risk of morbidity and mortality. Although advances in gene sequencing technologies have identified several genetic variants that may regulate the development and progression of T2DM, little is known about whether or not the variants are involved in disease progression and how these genetic variants are associated with diabetic neuropathy specifically. Significant missing heritability data and complex disease etiologies remain to be explained. This article is the first to provide a review of the genetic risk variants implicated in the diabetic neuropathies and to highlight potential commonalities. We thereby aim to contribute to the creation of a genetic-metabolic model that will help to elucidate the cause of diabetic neuropathies, evaluate a patient’s risk profile, and ultimately facilitate preventative and targeted treatment for the individual.

[1]  P. Oates Aldose reductase inhibitors and diabetic kidney disease. , 2010, Current opinion in investigational drugs.

[2]  C. Zoccali,et al.  Autonomic function in uremic patients treated by hemodialysis or CAPD and in transplant patients. , 1986, Clinical nephrology.

[3]  Jørgen K. Kanters,et al.  Cardiac repolarization during hypoglycaemia and hypoxaemia in healthy males: impact of renin-angiotensin system activity. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  V. Lyssenko,et al.  Genetics of diabetes complications , 2014, Mammalian Genome.

[5]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[6]  R. Vasan,et al.  Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels , 2011, Circulation research.

[7]  Tian-biao Zhou,et al.  Meta‐analysis of the relationship between ACE I/D gene polymorphism and end‐stage renal disease in patients with diabetic nephropathy , 2012, Nephrology.

[8]  T. Hansen,et al.  What Is the Contribution of Two Genetic Variants Regulating VEGF Levels to Type 2 Diabetes Risk and to Microvascular Complications? , 2013, PloS one.

[9]  Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  T. Hayashi,et al.  Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. , 2007, Kidney international. Supplement.

[11]  J. Jonas,et al.  Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. , 2012, Ophthalmology.

[12]  Jean Tichet,et al.  Gene polymorphisms of the renin‐angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study , 1998, Journal of hypertension.

[13]  G. Mamikunian,et al.  Cardiac Autonomic Imbalance in Newly Diagnosed and Established Diabetes Is Associated with Markers of Adipose Tissue Inflammation , 2011, Experimental diabetes research.

[14]  E. Jaimes,et al.  Role of L-arginine in the pathogenesis and treatment of renal disease. , 2004, The Journal of nutrition.

[15]  E. Maltezos,et al.  An insertion/deletion polymorphism in the alpha2B adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[16]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[17]  N. Karakuş,et al.  Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy , 2013, Molecular vision.

[18]  Lequn Li,et al.  Methylenetetrahydrofolate Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus , 2013, PloS one.

[19]  Dyah Purnamasari,et al.  ACE gene polymorphism and atherosclerotic lesion of carotid artery among offsprings of type 2 diabetes mellitus. , 2012, Acta medica Indonesiana.

[20]  P. Oates Aldose reductase, still a compelling target for diabetic neuropathy. , 2008, Current drug targets.

[21]  A. Chakravarti,et al.  Associations Between Hypertension and Genes in the Renin-Angiotensin System , 2003, Hypertension.

[22]  C. Bănescu,et al.  Vascular Endothelial Growth Factor Insertion/Deletion gene polymorphism in patients with type 2 diabetes and diabetic peripheral polyneuropathy , 2014 .

[23]  N. Palmer,et al.  Diabetic nephropathy: FRMD3 in diabetic nephropathy—guilt by association , 2013, Nature Reviews Nephrology.

[24]  H. Hammes,et al.  Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. , 2005, Diabetes.

[25]  I. G. Fantus,et al.  High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. , 2002, American journal of physiology. Endocrinology and metabolism.

[26]  D. Yarnitsky,et al.  Paradoxical heat sensation in uremic polyneuropathy , 1995, Muscle & nerve.

[27]  M. Shen,et al.  Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.

[28]  Yusuke Nakamura,et al.  Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes , 2010, Diabetes.

[29]  S. Chan,et al.  Null association between ACE gene I/D polymorphism and diabetic nephropathy among multiethnic Malaysian subjects , 2010, Indian journal of human genetics.

[30]  H. Rakugi,et al.  ACE Insertion/Deletion Polymorphism and Cardiovascular Effect of Hypercholesterolemia. , 2015, Journal of atherosclerosis and thrombosis.

[31]  G. Dibona,et al.  Neural control of renal function. , 2011, Comprehensive Physiology.

[32]  T. Nakagawa Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. , 2007, American journal of physiology. Renal physiology.

[33]  Archana Singh,et al.  Role of the renin angiotensin system in diabetic nephropathy. , 2010, World journal of diabetes.

[34]  M. Mattson,et al.  Toll-like receptors 2 and 4 modulate autonomic control of heart rate and energy metabolism , 2014, Brain, Behavior, and Immunity.

[35]  Gary C. Brown,et al.  ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION , 2012, Retina.

[36]  P. Osaadon,et al.  A review of anti-VEGF agents for proliferative diabetic retinopathy , 2014, Eye.

[37]  H. Ross,et al.  Nitric oxide and cardiac autonomic control in humans. , 2000, Hypertension.

[38]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[39]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[40]  E. Feldman,et al.  Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy , 2013, Experimental Neurology.

[41]  K. Kostev,et al.  Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany. , 2012, Primary care diabetes.

[42]  Melissa J. Morine,et al.  Next-generation sequencing identifies TGF-β1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy. , 2012, Biochimica et biophysica acta.

[43]  A. Levy,et al.  The genetics of vascular complications in diabetes mellitus. , 2010, Cardiology clinics.

[44]  O. Hill A Twin Study , 1968, British Journal of Psychiatry.

[45]  M. Cooper,et al.  Mechanisms of diabetic complications. , 2013, Physiological reviews.

[46]  A. D. den Hollander,et al.  Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. , 2014, Ophthalmology.

[47]  P. Binkley,et al.  A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. , 2005, American heart journal.

[48]  D. Margolis,et al.  Diabetes, lower extremity amputation, loss of protective sensation, and neuronal nitric oxide synthase associated protein in the Chronic Renal Insufficiency Cohort study , 2013, Wound Repair and Regeneration.

[49]  C. Winkler,et al.  Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  Influence of apolipoprotein E genotype on the response to caloric restriction in type 2 diabetic patients with hyperlipidaemia , 2003, Diabetes, obesity & metabolism.

[51]  S. Massry Is parathyroid hormone a uremic toxin? , 1977, Nephron.

[52]  S. Grant,et al.  Genetic Susceptibility to Type 2 Diabetes and Obesity: Follow-Up of Findings from Genome-Wide Association Studies , 2014, International journal of endocrinology.

[53]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[54]  A. Settin,et al.  Association of ACE and MTHFR genetic polymorphisms with type 2 diabetes mellitus: Susceptibility and complications , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[55]  C. Guja,et al.  Identification of gene variants in NOS3, ET-1 and RAS that confer risk and protection against microangiopathy in type 2 diabetic obese subjects. , 2011, Biochemical and biophysical research communications.

[56]  E. Feldman,et al.  Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy , 2009, Diabetes.

[57]  N. Yorioka,et al.  T-786→C Polymorphism of the Endothelial Nitric Oxide Synthase Gene Influences the Progression of Renal Disease , 2002, Nephron.

[58]  Apolipoprotein E gene polymorphism and its effect on anthropometric measures in normoglycemic subjects and type 2 diabetes , 2012, Journal of Diabetes & Metabolic Disorders.

[59]  G. Said,et al.  Diabetic neuropathy—a review , 2007, Nature Clinical Practice Neurology.

[60]  O. Melemedjian,et al.  Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment , 2013, Molecular pain.

[61]  F. Wang,et al.  Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. , 2015, The lancet. Diabetes & endocrinology.

[62]  D Crisan,et al.  Angiotensin I-Converting Enzyme Genotype and Disease Associations , 2000 .

[63]  J. Felício,et al.  Autonomic neuropathy tests correlate with left ventricular mass and cardiac diastolic function in normotensive patients with type 2 diabetes mellitus and without left ventricular hypertrophy. , 2010, Experimental and clinical cardiology.

[64]  M. Itoh,et al.  Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. , 2006, Endocrine journal.

[65]  D. Tárnoki,et al.  Effects of genetic vs. environmental factors on cardiovascular autonomic function: a twin study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[66]  S. Kaya,et al.  High Association of IL-4 Gene Intron 3 VNTR Polymorphism with Diabetic Peripheral Neuropathy , 2013, Journal of Molecular Neuroscience.

[67]  Y. Fujio,et al.  MTHFR gene polymorphism and diabetic retinopathy. , 2006, Current diabetes reviews.

[68]  D. D. de Luis,et al.  Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. , 2004, Journal of diabetes and its complications.

[69]  Z. Fang,et al.  Human genetics of diabetic vascular complications , 2013, Journal of Genetics.

[70]  P. Seshiah,et al.  Angiotensin II Stimulation of NAD(P)H Oxidase Activity: Upstream Mediators , 2002, Circulation research.

[71]  W. So,et al.  Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 −455T>C polymorphisms on the susceptibility to diabetic nephropathy , 2006, Clinical genetics.

[72]  Michael J. González,et al.  Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. , 2011, Current clinical pharmacology.

[73]  J. Blackwell,et al.  A Genome‐Wide Search for Type 2 Diabetes Susceptibility Genes in an Extended Arab Family , 2013, Annals of human genetics.

[74]  A. Hishida,et al.  Cardiac Autonomic Neuropathy in Patients with Chronic Renal Failure on Hemodialysis , 2000, Nephron.

[75]  S. Araki APOE polymorphism and diabetic nephropathy , 2014, Clinical and Experimental Nephrology.

[76]  Mark I McCarthy,et al.  Genomics, type 2 diabetes, and obesity. , 2010, The New England journal of medicine.

[77]  R. Bilous,et al.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[78]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[79]  K. Yamauchi,et al.  Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. , 2013, Endocrine journal.

[80]  Herbert F. Jelinek,et al.  Complexity of heart rate variability in type 2 diabetes - effect of hyperglycemia , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[81]  W. Hörl,et al.  A preceding exchange with polyglucose versus glucose solution modifies peritoneal equilibration test results. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[82]  G. Murray,et al.  Association of apolipoprotein E polymorphism with outcome after head injury , 1997, The Lancet.

[83]  O. Dekkers,et al.  Genetic associations in diabetic nephropathy: a meta-analysis , 2010, Diabetologia.

[84]  J. Jenkins Ethical implications of genetic information. , 2001, Online journal of issues in nursing.

[85]  S. Morris,et al.  Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation. , 2014, American journal of physiology. Renal physiology.

[86]  Raymond Vanholder,et al.  Normal and pathologic concentrations of uremic toxins. , 2012, Journal of the American Society of Nephrology : JASN.

[87]  A. Tuttolomondo,et al.  Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity , 2010, Cardiovascular diabetology.

[88]  G. Arsos,et al.  Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. , 2006, Journal of diabetes and its complications.

[89]  A. Vinik,et al.  Diabetic neuropathies. , 2004, The Medical clinics of North America.

[90]  A. Bhansali,et al.  Endothelial Nitric Oxide Synthase Gene Polymorphism and the Risk of Diabetic Neuropathy in Asian Indian Patients with Type 2 Diabetes , 2013 .

[91]  C. Bolton Peripheral Neurophathies Associated With Chronic Renal Failure , 1980, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[92]  K. Santos,et al.  The presence of allele D of angiotensin‐converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[93]  M. Klinger,et al.  The effect of high-tone external muscle stimulation on symptoms and electrophysiological parameters of uremic peripheral neuropathy. , 2012, Clinical nephrology.

[94]  S. Rich,et al.  Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. , 2000, Kidney international.

[95]  Herbert F. Jelinek,et al.  Association of cardiovascular risk using non-linear heart rate variability measures with the framingham risk score in a rural population , 2013, Front. Physiol..

[96]  Pin-Lan Li,et al.  Mechanisms of Homocysteine-Induced Glomerular Injury and Sclerosis , 2007, American Journal of Nephrology.

[97]  Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. , 2002, Seminars in cell & developmental biology.

[98]  L. Niskanen,et al.  Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[99]  F. Najafi,et al.  Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. , 2010, Clinical biochemistry.

[100]  Yusuke Nakamura,et al.  Combinational effect of genes for the renin–angiotensin system in conferring susceptibility to diabetic nephropathy , 2006, Journal of Human Genetics.

[101]  I. Strokov,et al.  The 262T>C promoter polymorphism of the catalase gene is associated with diabetic neuropathy in type 1 diabetic Russian patients. , 2006, Diabetes & metabolism.

[102]  K. Yamada,et al.  Association of an (A–C)n dinucleotide repeat polymorphic marker at the 5′‐region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[103]  J. Alroy,et al.  Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy , 2000, Nature Medicine.

[104]  E. Zintzaras,et al.  A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: The CUMAGAS-PAD database. , 2009, American journal of epidemiology.

[105]  Kate E Schemmel,et al.  Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. , 2010, Journal of diabetes and its complications.

[106]  V. Nielsen RECOVERY FROM PERIPHERAL NEUROPATHY AFTER RENAL TRANSPLANTATION , 1970, Acta neurologica Scandinavica.

[107]  F. Likis Folic Acid. , 2016, Journal of midwifery & women's health.

[108]  Jeffrey A. Cohen,et al.  Increasing homocysteine levels and diabetic autonomic neuropathy , 2001, Autonomic Neuroscience.

[109]  T. Motawi,et al.  Alterations in circulating angiogenic and anti‐angiogenic factors in type 2 diabetic patients with neuropathy , 2014, Cell biochemistry and function.

[110]  N. Tong,et al.  Angiotensin-converting enzyme I/D polymorphism and diabetic peripheral neuropathy in type 2 diabetes mellitus: A meta-analysis , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[111]  G. Novelli,et al.  TCF7L2 gene polymorphisms and type 2 diabetes: association with diabetic retinopathy and cardiovascular autonomic neuropathy , 2013, Acta Diabetologica.

[112]  S. Hampson Randomised, placebo-controlled trial , 2002 .

[113]  R M Heethaar,et al.  Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. , 2001, Diabetes care.

[114]  P. Berlit,et al.  Neurologic complications of acute and chronic renal disease. , 2014, Handbook of clinical neurology.

[115]  K. Santos,et al.  The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. , 2005, Diabetes.

[116]  Chih-Hsing Wu,et al.  Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. , 2007, The Journal of clinical endocrinology and metabolism.

[117]  T. Hansen,et al.  A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes , 2010, PLoS genetics.

[118]  T. Hansen,et al.  Polymorphisms in the 3′ UTR in the neurocalcin δ gene affect mRNA stability, and confer susceptibility to diabetic nephropathy , 2007, Human Genetics.

[119]  P. Valensi,et al.  Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study. , 2003, Metabolism: clinical and experimental.

[120]  Yusuke Nakamura,et al.  Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. , 2003, Diabetes.

[121]  R. Kawamori,et al.  Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. , 2006, Diabetes research and clinical practice.

[122]  Jiayan Huang,et al.  VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.

[123]  Jasmin Divers,et al.  A genome-wide association study for diabetic nephropathy genes in African Americans. , 2011, Kidney international.

[124]  S. Maeda Genome-wide search for susceptibility gene to diabetic nephropathy by gene-based SNP. , 2004, Diabetes research and clinical practice.

[125]  I. Fermo,et al.  The Role of Vitamin B12 in Fasting Hyperhomocysteinemia and Its Interaction with the Homozygous C677T Mutation of the Methylenetetrahydrofolate Reductase (MTHFR) Gene , 2000, Thrombosis and Haemostasis.

[126]  S. Janković,et al.  An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure. , 2013, Journal of cardiology.

[127]  H. Jelinek,et al.  Angiotensin-converting enzyme gene DD genotype is associated with increased systolic blood pressure in an Australian Rural Type 2 Diabetic Cohort , 2013, Hypertension Research.

[128]  A. Donker,et al.  Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial , 2010, BMJ : British Medical Journal.

[129]  P. Donnan,et al.  Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study , 2008, Pharmacogenetics and genomics.

[130]  Saurabh Sharma,et al.  Potential role of nitric oxide synthase isoforms in pathophysiology of neuropathic pain , 2014, Inflammopharmacology.

[131]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Nerve Dysfunction , 2007 .

[132]  A. Vinik,et al.  Neuropathy: The Crystal Ball for Cardiovascular Disease? , 2010, Diabetes Care.

[133]  J. Townend,et al.  The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction , 2002, Clinical Autonomic Research.

[134]  Erdem Buyukbingol,et al.  Recent studies of aldose reductase enzyme inhibition for diabetic complications. , 2003, Current medicinal chemistry.

[135]  M. Matsuda,et al.  Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. , 2004, Diabetes care.

[136]  M. Cooper The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. , 2004, American journal of hypertension.

[137]  W. Berger,et al.  Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.

[138]  H. Sone,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[139]  H. Superko,et al.  Statins personalized. , 2012, The Medical clinics of North America.

[140]  B. Glaser,et al.  Predicting Diabetic Nephropathy Using a Multifactorial Genetic Model , 2011, PloS one.

[141]  P. Vokonas,et al.  Cardiac Autonomic Dysfunction: Effects From Particulate Air Pollution and Protection by Dietary Methyl Nutrients and Metabolic Polymorphisms , 2008, Circulation.

[142]  P. Kempler,et al.  Diabetic neuropathy: new strategies for treatment , 2007, Diabetes, obesity & metabolism.

[143]  F. Q. Ribeiro The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[144]  J. Morgenlander,et al.  Peripheral neuropathy in patients with chronic renal failure. A treatable source of discomfort and disability. , 1997, Postgraduate medicine.

[145]  Guoliang Huang,et al.  MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis. , 2013, Metabolism: clinical and experimental.

[146]  Gangyi Yang,et al.  Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis , 2014, PloS one.

[147]  A Voss,et al.  Angiotensin-converting enzyme and angiotensinogen gene polymorphisms and heart rate variability in twins. , 1998, The American journal of cardiology.

[148]  S. Humphries,et al.  Association between the rs1050450 glutathione peroxidase-1 (C > T) gene variant and peripheral neuropathy in two independent samples of subjects with diabetes mellitus. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[149]  K. Suszták,et al.  Transcriptome Analysis of Human Diabetic Kidney Disease , 2011, Diabetes.

[150]  Felix Eichinger,et al.  Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.

[151]  Toshiko Tanaka,et al.  Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. , 2009, American journal of human genetics.

[152]  P. Lanting,et al.  Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor , 2004, Journal of Neurology.

[153]  P. Deyn,et al.  Neurological complications in renal failure: a review , 2004, Clinical Neurology and Neurosurgery.

[154]  L. Niskanen,et al.  Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. , 2004, Diabetes care.

[155]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[156]  D. Wright,et al.  Inflammatory Mediators in Diabetic Neuropathy , 2012 .

[157]  Z. Rahimi,et al.  eNOS 4a/b Polymorphism and Its Interaction with eNOS G894T Variants in Type 2 Diabetes Mellitus: Modifying the Risk of Diabetic Nephropathy , 2013, Disease markers.

[158]  J. Melvin,et al.  Neuropathy in end-stage renal disease secondary to primary renal disease and diabetes. , 1984, Archives of physical medicine and rehabilitation.

[159]  John V Pearson,et al.  Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study , 2007, Diabetes.

[160]  D. Santoro,et al.  Autonomic dysfunction in uremia. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[161]  A. Izenberg,et al.  Diabetic Neuropathies , 2015, Seminars in Neurology.

[162]  T. Benstead,et al.  Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. , 2007, The Cochrane database of systematic reviews.

[163]  K. Isshiki,et al.  Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. , 2001, Kidney international.

[164]  V. Lánská,et al.  Impact of variants within seven candidate genes on statin treatment efficacy. , 2011, Physiological research.

[165]  M. Kiernan,et al.  Uremic neuropathy: Clinical features and new pathophysiological insights , 2007, Muscle & nerve.

[166]  M. Brownlee Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[167]  G. Lundborg,et al.  Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.

[168]  C. Colton,et al.  An Apolipoprotein E-Mimetic Stimulates Axonal Regeneration and Remyelination after Peripheral Nerve Injury , 2010, Journal of Pharmacology and Experimental Therapeutics.

[169]  M. B. Brown,et al.  Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. , 1988, The New England journal of medicine.

[170]  R. Bedlack,et al.  Apolipoprotein E and neuromuscular disease: a critical review of the literature. , 2000, Archives of neurology.

[171]  N. Katsilambros,et al.  The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. , 2011, Journal of diabetes and its complications.

[172]  A. Toscano,et al.  Uremic vagal neuropathy: has parathyroid hormone a pathogenetic role? , 1986, Functional neurology.

[173]  Rayaz A. Malik,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[174]  D. Gaudet,et al.  The potential applications of Apolipoprotein E in personalized medicine , 2014, Front. Aging Neurosci..

[175]  A. Liberati,et al.  A Meta‐analysis of Trials on Aldose Reductase Inhibitors in Diabetic Peripheral Neuropathy , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[176]  B. Larijani,et al.  Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications. , 2011, Diabetes research and clinical practice.

[177]  J. Kessler Vascular endothelial growth factor gene transfer for diabetic polyneuropathy , 2009, Annals of neurology.

[178]  Andrew Stranieri,et al.  An approach for Ewing test selection to support the clinical assessment of cardiac autonomic neuropathy , 2013, Artif. Intell. Medicine.

[179]  K. Thangaraj,et al.  Novel mutations in ATPase 8, ND1 and ND5 genes associated with peripheral neuropathy of diabetes. , 2014, Diabetes research and clinical practice.

[180]  A. Demaine,et al.  Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene , 1998, Journal of neurology, neurosurgery, and psychiatry.

[181]  K. Arimura,et al.  Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[182]  R. Guymer,et al.  Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. , 2013, Ophthalmology.

[183]  Rania Naguib Abdel Mouteleb Abdel Reheem,et al.  Serum vitamin D and parathormone (PTH) concentrations as predictors of the development and severity of diabetic retinopathy , 2013 .

[184]  K. Kuboki,et al.  Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. , 2001, Journal of diabetes and its complications.

[185]  Herbert F. Jelinek,et al.  Using renyi entropy to detect early cardiac autonomic neuropathy , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[186]  Q. Mansoor,et al.  Angiotensin‐converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus , 2012, Journal of diabetes.

[187]  B. Isermann,et al.  Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. , 2004, Diabetes care.

[188]  T. Tanimoto,et al.  Correlation between erythrocyte aldose reductase level and human diabetic retinopathy , 2002, The British journal of ophthalmology.

[189]  H. Gerstein Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO‐HOPE , 2002, Diabetes/metabolism research and reviews.

[190]  J. Halter,et al.  Autonomic Neural Dysfunction in Recently Diagnosed Diabetic Subjects , 1984, Diabetes Care.

[191]  D. Soni,et al.  Plasma Homocysteine level and its clinical correlation with type 2 diabetes mellitus and its complications , 2014, International Journal of Diabetes in Developing Countries.

[192]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[193]  A. Hung,et al.  An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease , 2006, Human Genetics.

[194]  H. Parving,et al.  Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? , 2006, Kidney international.

[195]  Xilin Yang,et al.  Aldose Reductase Genotypes and Cardiorenal Complications , 2008, Diabetes Care.

[196]  T. Moritani,et al.  T393C polymorphism of GNAS1 associated with the autonomic nervous system in young, healthy Japanese subjects , 2004, Clinical and experimental pharmacology & physiology.

[197]  H. Lidov,et al.  Rapid reversal of uremic neuropathy following renal transplantation in an adolescent , 2012, Pediatric Transplantation.

[198]  M. Lenhard,et al.  Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. , 2005, The Journal of clinical endocrinology and metabolism.

[199]  C. Mathews,et al.  Role of SREBP-1 in the Development of Parasympathetic Dysfunction in the Hearts of Type 1 Diabetic Akita Mice , 2009, Circulation research.

[200]  E. G. Erdös,et al.  Angiotensin I converting enzyme. , 1975, Circulation research.

[201]  M. John,et al.  Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications. , 2008, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[202]  N. Olivarius,et al.  Amputations and foot ulcers in patients newly diagnosed with Type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co‐morbidity , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[203]  M. Bartelink,et al.  Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. , 2002, Diabetes care.

[204]  B. Canaud,et al.  Beta2-microglobulin, a uremic toxin with a double meaning. , 2006, Kidney international.

[205]  E. Kobyliansky,et al.  Heritability of circulating growth factors involved in the angiogenesis in healthy human population. , 2004, Cytokine.

[206]  A. Demaine,et al.  Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reductase gene may account for the association with diabetic microvascular complications. , 2003, Biochimica et biophysica acta.

[207]  R. Freeman,et al.  Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management , 2011, Diabetes/metabolism research and reviews.

[208]  Yu Zhang,et al.  Association between MTHFR A1298C polymorphism and neural tube defect susceptibility: a metaanalysis. , 2012, American journal of obstetrics and gynecology.

[209]  J. Mega,et al.  Identification of Genetic Variants Associated With Response to Statin Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[210]  F. Boomsma,et al.  NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity. , 2008, Journal of applied physiology.

[211]  M. Craig,et al.  Decline in Neurophysiological Function After 7 Years in an Adolescent Diabetic Cohort and the Role of Aldose Reductase Gene Polymorphisms A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[212]  S. Chung,et al.  Genetic analysis of aldose reductase in diabetic complications. , 2003, Current medicinal chemistry.

[213]  Yusuke Nakamura,et al.  A Single Nucleotide Polymorphism in KCNQ1 Is Associated With Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes , 2010, Diabetes Care.

[214]  Rodica Pop-Busui,et al.  Cardiac Autonomic Neuropathy in Diabetes , 2010, Diabetes Care.

[215]  J. Gross,et al.  The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. , 2003, Diabetes.

[216]  A. Tuttolomondo,et al.  Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. , 2008, Metabolism: clinical and experimental.

[217]  R. Kawamori,et al.  Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[218]  Shaughnessy Sl,et al.  A 'clinical perspective'. , 1977 .

[219]  Is the C677T polymorphism in methylenetetrahydrofolate reductase gene or plasma homocysteine a risk factor for diabetic peripheral neuropathy in Chinese individuals?☆ , 2012, Neural regeneration research.

[220]  T. Moritani,et al.  Association of beta-adrenoceptor polymorphisms with cardiac autonomic modulation in Japanese males. , 2007, American heart journal.

[221]  D. Feinfeld,et al.  Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. , 1978, The New England journal of medicine.

[222]  I. Nishio,et al.  [Angiotensin I converting enzyme]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[223]  C. Eccleston,et al.  Systematic review and meta-analysis of psychological therapies for children with chronic pain. , 2014, Journal of pediatric psychology.

[224]  J. Baluarte Neurological Complications of Renal Disease. , 2017, Seminars in pediatric neurology.

[225]  S. Dixit,et al.  Diabetic peripheral neuropathy and its evaluation in a clinical scenario: a review. , 2014, Journal of postgraduate medicine.

[226]  Yusuke Nakamura,et al.  Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes , 2011, Clinical and Experimental Nephrology.

[227]  Dan Ziegler,et al.  Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.

[228]  E. Maltezos,et al.  APOE gene polymorphisms and diabetic peripheral neuropathy , 2012, Archives of medical science : AMS.

[229]  E. Feldman,et al.  The role of growth factors in diabetic peripheral neuropathy , 2004, Journal of the peripheral nervous system : JPNS.

[230]  A. Krolewski,et al.  The genetic risk of kidney disease in type 2 diabetes. , 2013, The Medical clinics of North America.

[231]  A. Hoke,et al.  APOE ε4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy , 2005, Neurology.

[232]  Marimuthu Palaniswami,et al.  Association of cardiac autonomic neuropathy with alteration of sympatho-vagal balance through heart rate variability analysis. , 2010, Medical engineering & physics.

[233]  J. Steimle,et al.  L-Arginine Supplementation in Type II Diabetic Rats Preserves Renal Function and Improves Insulin Sensitivity by Altering the Nitric Oxide Pathway , 2014, International journal of endocrinology.

[234]  W. Młynarski,et al.  Circadian blood pressure variation in normotensive type 2 diabetes patients and angiotensin converting enzyme polymorphism. , 2008, Diabetes research and clinical practice.

[235]  H. Aggarwal,et al.  Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease , 2013, Renal failure.

[236]  V. Athyros,et al.  Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. , 1998, Acta cardiologica.

[237]  R. Holder,et al.  The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[238]  J. Lunceford,et al.  ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[239]  V. Kolla,et al.  Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. , 2009, Cytokine.

[240]  S. Jordan Complement fixing donor‐specific antibodies and allograft loss , 2012, Pediatric transplantation.

[241]  C. Guja,et al.  Role of Nitric Oxide Synthase Family in Diabetic Neuropathy , 2012 .

[242]  C. Jung,et al.  Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients , 2012, Cardiovascular Diabetology.

[243]  S. Visvikis-Siest,et al.  Heritability for Plasma VEGF Concentration in the Stanislas Family Study , 2007, Annals of human genetics.

[244]  K. Santos,et al.  Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. , 2005, Journal of nephrology.

[245]  H. Prydz A New Paradigm for Blood Coagulation Research , 2000, Thrombosis and Haemostasis.

[246]  T. Murano,et al.  [The examination of apoE phenotypes in diabetic patients with peripheral neuropathy]. , 1998, Rinsho byori. The Japanese journal of clinical pathology.

[247]  B. J. Klevering,et al.  Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.

[248]  Z. Rahimi ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. , 2012, Journal of nephropathology.

[249]  S. Ha ACE Insertion/Deletion Polymorphism and Diabetic Nephropathy: Clinical Implications of Genetic Information , 2014, Journal of diabetes research.

[250]  E. Brennan,et al.  The Genetics of Diabetic Nephropathy , 2013, Genes.

[251]  Z. Massy,et al.  Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. , 2012, Kidney international.

[252]  N. Cao,et al.  VEGF Genetic Polymorphisms May Contribute to the Risk of Diabetic Nephropathy in Patients with Diabetes Mellitus: A Meta-Analysis , 2014, TheScientificWorldJournal.

[253]  Ambady Ramachandran,et al.  High prevalence and early onset of cardiac autonomic neuropathy among South Indian type 2 diabetic patients with nephropathy. , 2000, Diabetes research and clinical practice.

[254]  M. Laakso,et al.  Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. , 1993, Atherosclerosis.

[255]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[256]  N. Hamajima,et al.  Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[257]  I. Degirmenci,et al.  Frequency of angiotensin‐converting enzyme gene polymorphism in Turkish type 2 diabetic patients , 2005, International journal of clinical practice.

[258]  K. Nanjo,et al.  Uncoupling protein 2 promoter polymorphism -866G/A affects peripheral nerve dysfunction in Japanese type 2 diabetic patients. , 2006, Diabetes care.

[259]  D. Selvarajah,et al.  Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy , 2012, Diabetes/metabolism research and reviews.

[260]  A. Saunders,et al.  APOE genotype is a risk factor for neuropathy severity in diabetic patients , 2003, Neurology.

[261]  F. Santilli,et al.  CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. , 2009, Journal of atherosclerosis and thrombosis.

[262]  M. Černá,et al.  Polymorphisms in the Vitamin D Receptor Gene and Parathyroid Hormone Gene in the Development and Progression of Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease , 2012, Kidney and Blood Pressure Research.

[263]  P. Magnusson,et al.  Genetic Influences on Peripheral Arterial Disease in a Twin Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[264]  Jing Zhang,et al.  Association study of angiotensin converting enzyme gene polymorphism with elderly diabetic hypertension and lipids levels , 2013, Lipids in Health and Disease.

[265]  S. Voidăzan,et al.  Cardiovascular Autonomic Neuropathy in Context of Other Complications of Type 2 Diabetes Mellitus , 2013, BioMed research international.

[266]  Ryuzo Kawamori,et al.  RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. , 2003, Diabetes care.

[267]  A. Tahrani,et al.  Cardiac autonomic neuropathy in patients with diabetes mellitus. , 2014, World journal of diabetes.

[268]  K. Santos,et al.  Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis , 2014, BMC Medical Genetics.

[269]  A. de Leiva,et al.  Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? , 1998, Diabetologia.

[270]  R. Ribchester,et al.  ApoE isoform-specific regulation of regeneration in the peripheral nervous system. , 2011, Human molecular genetics.

[271]  G. Remuzzi,et al.  Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[272]  Jemal H. Abawajy,et al.  Enhancing Predictive Accuracy of Cardiac Autonomic Neuropathy Using Blood Biochemistry Features and Iterative Multitier Ensembles , 2016, IEEE Journal of Biomedical and Health Informatics.

[273]  Yusuke Nakamura,et al.  Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. , 2005, Diabetes.

[274]  E. Elstner,et al.  Homocysteine-Induced Oxidative Damage: Mechanisms and Possible Roles in Neurodegenerative and Atherogenic Processes , 1995, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[275]  E. Benjamin,et al.  Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. , 2009, European heart journal.

[276]  S. Yadav Glycemic control in diabetic kidney disease patients , 2012 .

[277]  M. Kuehl,et al.  Cardiovascular autonomic neuropathies as complications of diabetes mellitus , 2012, Nature Reviews Endocrinology.

[278]  A. Khandoker,et al.  Pulse wave analysis using tone-entropy algorithm in people with and without foot complaints in a rural diabetes screening clinic , 2011 .

[279]  M. El-Bradey,et al.  Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti‐vascular endothelial growth factor treatment outcomes , 2014, Clinical & experimental ophthalmology.

[280]  Soujatya Dhar,et al.  Polymorphism of ACE gene as the genetic predisposition of coronary artery disease in Eastern India. , 2012, Indian heart journal.

[281]  W. Schady,et al.  Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial , 1998, The Lancet.

[282]  A. Krolewski,et al.  An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. , 2008, Kidney international.

[283]  J. Egido,et al.  Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy , 2011, Mediators of inflammation.

[284]  S. Yagihashi,et al.  Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients , 2001, Virchows Archiv.

[285]  B. Cronstein,et al.  Metaanalysis of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms Affecting Methotrexate Toxicity , 2009, The Journal of Rheumatology.

[286]  T. Erbas,et al.  Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels , 2005, Journal of internal medicine.

[287]  Y. Wettergren,et al.  Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer. , 2011, Anticancer research.

[288]  C. Johnston Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. , 1994, Hypertension.

[289]  J. Arezzo,et al.  Diabetic somatic neuropathies. , 2004, Diabetes care.

[290]  W. Almawi,et al.  Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. , 2008, Journal of diabetes and its complications.

[291]  A. Tuttolomondo,et al.  Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. , 2012, Cytokine.

[292]  E. Vasquez,et al.  Cardiovascular Autonomic Imbalance and Baroreflex Dysfunction in the Apolipoprotein E-deficient Mouse , 2012, Cellular Physiology and Biochemistry.

[293]  A. Cox,et al.  Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[294]  M. Mittlböck,et al.  Influence of Methylenetetrahydrofolate Reductase Gene Polymorphisms on Homocysteine Concentrations after Nitrous Oxide Anesthesia , 2008, Anesthesiology.

[295]  R. Lattanzio,et al.  The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.